Advaxis, Inc. (ADXS): Daniel O’connor , Chief Executive Officer of Advaxis, Inc. sold 8,237 shares on May 2, 2016. The Insider selling transaction was reported by the company on May 2, 2016 to the Securities and Exchange Commission. The shares were sold at $7.51 per share for a total value of $61,859.87 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Feb 1, 2016, Robert Petit (Chief Scientific Officer) sold 3,099 shares at $6.88 per share price.On Feb 1, 2016, Daniel O’connor (Chief Executive Officer) sold 8,818 shares at $6.88 per share price.Also, On Dec 21, 2015, Richard J Berman (director) sold 14,332 shares at $12.39 per share price.On Oct 22, 2015, David J Mauro (Chief Medical Officer) sold 24,586 shares at $10.08 per share price.
Shares of Advaxis (ADXS) ended Wednesday, Apr 27, 2016 session in red amid volatile trading. The shares closed down -0.63 points or -7.25% at $8.06 with 9,88,673 shares getting traded. Post opening the session at $8.51, the shares hit an intraday low of $7.95 and an intraday high of $8.71 and the price vacillated in this range throughout the day. The company has a market cap of $275 M and the number of outstanding shares has been calculated to be 3,41,01,368 shares. The 52-week high of Advaxis is $30.13 and the 52-week low is $5.21.
Advaxis Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on developing various cancer immunotherapies that use the bodys natural immune system to redirect the immune response to kill cancer. Its Lm Technology is a cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralizes regulatory T cells and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Its Lm Technology immunotherapy axalimogene filolisbac (ADXS-HPV) targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase II in invasive cervical cancer Phase I/II in head and neck cancer and Phase I/II in anal cancer. It has preclinical program with immunotherapies in development for cancers and infectious diseases.